Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AnHeart Starts Global Phase II Trial of mIDH1 Inhibitor for Brain Cancer

publication date: Sep 7, 2023

AnHeart Therapeutics, a New York-Hangzhou biotech, dosed the first patient in a global Phase II trial of safusidenib in patients with mutant isocitrate dehydrogenase 1 (mIDH1) glioma, a common brain cancer. Safusidenib is a novel, oral mIDH1 inhibitor. In a Phase I trial, it has shown high blood-brain barrier penetration along with anti-tumor activity in patients with recurrent IDH1-mutant gliomas. AnHeart acquired global rights (except Japan) to safusidenib in 2020 from Daiichi Sankyo soon after it in-licensed global rights from Daiichi Sankyo for AnHeart’s lead drug, a next-gen ROS1-inhibitor currently in pivotal Phase II trials for ROS1-positive NSCLC. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here